Welcome!

News Feed Item

Spina Bifida Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spina Bifida Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280944/Spina-Bifida-Global-Clinical-Trials-Review-H2-2014.html

Spina Bifida Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spina Bifida Global Clinical Trials Review, H2, 2014" provides data on the Spina Bifida clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spina Bifida. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spina Bifida. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Spina Bifida 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Spina Bifida to Central Nervous System Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Spina Bifida to Central Nervous System Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Spina Bifida 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Prominent Drugs 25
Clinical Trial Profiles 26
Clinical Trial Overview of Top Companies 26
Tengion, Inc. 26
Clinical Trial Overview of Tengion, Inc. 26
Clinical Trial Overview of Top Institutes / Government 27
Eunice Kennedy Shriver National Institute of Child Health and Human Development 27
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 27
Centers for Disease Control and Prevention 28
Clinical Trial Overview of Centers for Disease Control and Prevention 28
William Beaumont Hospitals 29
Clinical Trial Overview of William Beaumont Hospitals 29
Aarhus University 30
Clinical Trial Overview of Aarhus University 30
Rennes University Hospital 31
Clinical Trial Overview of Rennes University Hospital 31
Baylor College of Medicine 32
Clinical Trial Overview of Baylor College of Medicine 32
UMC Utrecht Holding BV 33
Clinical Trial Overview of UMC Utrecht Holding BV 33
Universitaire Ziekenhuizen Leuven 34
Clinical Trial Overview of Universitaire Ziekenhuizen Leuven 34
University of New Mexico 35
Clinical Trial Overview of University of New Mexico 35
Duke University 36
Clinical Trial Overview of Duke University 36
Five Key Clinical Profiles 37
Appendix 56
Abbreviations 56
Definitions 56
Research Methodology 57
Secondary Research 57
About GlobalData 58
Contact Us 58
Disclaimer 58
Source 58

List of Tables

Spina Bifida Therapeutics, Global, Clinical Trials by Region, 2014* 6
Spina Bifida Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Spina Bifida Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Spina Bifida Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Spina Bifida Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Spina Bifida Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Spina Bifida to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Spina Bifida to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Spina Bifida Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 18
Spina Bifida Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Spina Bifida Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Spina Bifida Therapeutics, Global, Withdrawn Clinical Trials, 2014* 21
Spina Bifida Therapeutics, Global, Terminated Clinical Trials, 2014* 21
Spina Bifida Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Spina Bifida Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 23
Spina Bifida Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Spina Bifida Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 25
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Tengion, Inc., 2014* 26
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 27
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Centers for Disease Control and Prevention, 2014* 28
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by William Beaumont Hospitals, 2014* 29
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Aarhus University, 2014* 30
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Rennes University Hospital, 2014* 31
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Baylor College of Medicine, 2014* 32
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by UMC Utrecht Holding BV, 2014* 33
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Universitaire Ziekenhuizen Leuven, 2014* 34
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by University of New Mexico, 2014* 35
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 36

List of Figures

Spina Bifida Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Spina Bifida Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Spina Bifida Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Proportion of Spina Bifida to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Spina Bifida to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Spina Bifida Therapeutics, Global, Clinical Trials by Phase (%), 2014* 17
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 18
Spina Bifida Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Spina Bifida Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Spina Bifida Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Spina Bifida Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 23
GlobalData Methodology 57

To order this report: Spina Bifida Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280944/Spina-Bifida-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lead...
SYS-CON Events announced today that CAST Software will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CAST was founded more than 25 years ago to make the invisible visible. Built around the idea that even the best analytics on the market still leave blind spots for technical teams looking to deliver better software and prevent outages, CAST provides the software intelligence that matter ...
SYS-CON Events announced today that Daiya Industry will exhibit at the Japanese Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Ruby Development Inc. builds new services in short period of time and provides a continuous support of those services based on Ruby on Rails. For more information, please visit https://github.com/RubyDevInc.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
As businesses evolve, they need technology that is simple to help them succeed today and flexible enough to help them build for tomorrow. Chrome is fit for the workplace of the future — providing a secure, consistent user experience across a range of devices that can be used anywhere. In her session at 21st Cloud Expo, Vidya Nagarajan, a Senior Product Manager at Google, will take a look at various options as to how ChromeOS can be leveraged to interact with people on the devices, and formats th...
Is advanced scheduling in Kubernetes achievable? Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, will answer these questions and demonstrate techniques for implementing advanced scheduling. For example, using spot instances ...
First generation hyperconverged solutions have taken the data center by storm, rapidly proliferating in pockets everywhere to provide further consolidation of floor space and workloads. These first generation solutions are not without challenges, however. In his session at 21st Cloud Expo, Wes Talbert, a Principal Architect and results-driven enterprise sales leader at NetApp, will discuss how the HCI solution of tomorrow will integrate with the public cloud to deliver a quality hybrid cloud e...
SYS-CON Events announced today that Yuasa System will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Yuasa System is introducing a multi-purpose endurance testing system for flexible displays, OLED devices, flexible substrates, flat cables, and films in smartphones, wearables, automobiles, and healthcare.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
The session is centered around the tracing of systems on cloud using technologies like ebpf. The goal is to talk about what this technology is all about and what purpose it serves. In his session at 21st Cloud Expo, Shashank Jain, Development Architect at SAP, will touch upon concepts of observability in the cloud and also some of the challenges we have. Generally most cloud-based monitoring tools capture details at a very granular level. To troubleshoot problems this might not be good enough.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...